Phase ones can be designed as the sponsor companies see fit. They have much leeway in choice of population and inclusion criteria. So - you will find many precedents for both - the more 'broad-label' set-up of ctix phI, and the specific cancer type inclusion of the other company's trial. Preclinicals guide phI resource utilization. Preclinicals that consistently showed targeted action on one or two specific cancer types over others will lead to trial designed to maximize those results.